INFLUENCE OF TAURIN AT THE DEGREE OF INTERNAL OBESITY AND SEVERITY OF VISCERAL FAT DYSFUNCTION IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Cover Page

Cite item

Full Text

Abstract

Aim. To evaluate influence of 24 weeks taurin therapy on level of internal obesity and severity of visceral fat dysfunction in patients with non-alcoholic fatty liver disease (NAFLD). Materials and methods. A prospective comparative randomized trial that included 90 patients with NAFLD was conducted. NAFLD was diagnosed according to liver ultrasound results (using Siemens Sonoline G50, Germany ultrasound system with Doppler device and evaluation of liver parenchyma echogenicity, vascular pattern, and degree of distal echo signal attenuation). Using simple randomization method the patients were divided into 2 groups: group 1 (study group) included patients with NAFLD receiving taurin 1000 mg per day (500 mg 2 times daily) in addition to daily therapy for coexisting disorders (type 2 diabetes mellitus, ischemic heart disease, arterial hypertension) and group 2 (control group) that included patients with NAFLD receiving only baseline therapy. Body composition analysis with evaluation of visceral fat percentage content using bioelectrical impedansometry (Omron BF508 52, Japan) was performed, internal obesity index and severity of visceral fat dysfunction were determined at baseline and after 24 weeks of treatment. Carbohydrate metabolism state was controlled according to following parameters: fasting glucose serum level, basal insulin level, and Homeostasis Model Assessment of Insulin Resistance HOMA-IR. Total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein levels were evaluated for lipids metabolism status evaluation. Results. In patients with NAFLD severe internal obesity and severe visceral fat dysfunction worsening in proportion to obesity degree increase were observed. It was shown that use of 1000 mg taurin per day for 24 weeks in treatment of patients with NAFLD results in significant decrease of internal obesity degree according to bioimpedansometry, internal obesity index, and decrease of visceral fat dysfunction.

About the authors

Mikhail E. Statsenko

Volgograd State Medical University, Volgograd

Email: mestatsenko@rambler
д-р мед. наук, проф., зав. каф. внутренних болезней педиатрического и стоматологического фак-тов Volgograd, Russia

Svetlana V. Turkina

Volgograd State Medical University, Volgograd

д-р мед. наук, проф. каф. внутренних болезней педиатрического и стоматологического фак-тов Volgograd, Russia

Elena E. Gorbacheva

Volgograd State Medical University, Volgograd

аспирант каф. внутренних болезней педиатрического и стоматологического фак-тов Volgograd, Russia

Anna A. Ermolenko

Volgograd State Medical University, Volgograd

аспирант каф. внутренних болезней педиатрического и стоматологического фак-тов Volgograd, Russia

Marina A. Kosivtsova

Volgograd State Medical University, Volgograd

канд. мед. наук, доц. каф. внутренних болезней педиатрического и стоматологического фак-тов Volgograd, Russia

References

  1. Estes C, Anstee QM, Arias-Loste MT et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69: 896-904.
  2. Lonardo A, Bellentani S, Argo CK et al.; Non-alcoholic Fatty Liver Disease Study Group. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis 2015; 477: 997-1006.
  3. Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2015. doi: 10.1016/j.metabol.2015.1009.1017
  4. Bertolotti, M, Lonardo А, Mussi С et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol 2014; 20: 14185-204.
  5. Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6: 263-73.
  6. Amarapurkar DN, Hashimoto E, Lesmana LA et al. How common is non-alcoholic fatty liver disease in the Asia? Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-93.
  7. Tsuruta G, Tanaka N, Hongo M et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J Gastroenterol 2010; 45: 666-72.
  8. Berentzen TL, Gamborg M, Holst C et al. Body mass index in childhood and adult risk of primary liver cancer. J Hepatol 2014; 60: 325-30.
  9. Long MT, Gurary EB, Massaro JM et al. Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Liver Int 2019; 3 (4): 740-7.
  10. Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disea-se-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
  11. Rodella P, Takase L, dos Santos L et al. The Effect of Taurine on Hepatic Disorders [Version 2]. Curr Updates Hepatol Gastroenterol 2017; 1: 1.2.
  12. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-48.
  13. Kim SJ, Gupta RC, Lee HW. Taurine-diabetes interaction: from involvement to Protection. Curr Diabetes Rev 2007; 3: 165-75.
  14. Lourenco R, Camilo ME. Taurine: a conditionally essential amino acid in humans? An overview in health and disease. Nutr Hosp 2002; 17: 262-70.
  15. Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids 2014; 46: 7-20.
  16. Ripps H, Shen W. Review: taurine: a “very essential” amino acid. Mol Vis 2012; 18: 2673-86.
  17. Huxtable RJ. Physiological actions of taurine. Physiol Rev 1992; 72: 101-63.
  18. Murakami S. Role of taurine in the pathogenesis of obesity. Mol Nutr Food Res 2015; 59 (7): 1353-63.
  19. Murakami S. The physiological and pathophysiological roles of taurine in adipose tissue in relation to obesity. Life Sci 2017; 186: 80-6.
  20. Kim KS, Jang MJ, Fang S et al. Amino Acids 2019; 51: 245.
  21. Murakami S, Kondo Y Nagate T Effects of long-term treatment with taurine in mice fed a high-fat diet: improvement of cholesterol metabolism and vascular lipid accumulation by taurine. Adv Exp Med Biol 2000; 483: 177-86.
  22. De la Puerta C, Arrieta FJ, Balsa JA et al. Taurine and glucose metabolism: a review. Nutr Hosp 2010; 25: 910-9.
  23. Murakami S, Yamagishi I, Asami Y et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 1996; 52: 303-13.
  24. Iwakir Y Phatophysiology of Portal Hypertension. Clin Liver Dis 2014; 18: 281-91.
  25. Saito M, Hirano H, Yano Y et al. Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients. Hepatol Res 2015; 46: 215-24.
  26. Стаценко М.Е., Туркина С.В., Шилина Н.Н. и др. Фармакотерапия неалкогольной жировой болезни печени: акцент на фиброз. Consilium Medicum. 2018; 20 (8): 37-41. doi: 10.26442/2075-1753_2018.8.37-41. @@Statsenko M.E., Turkina S.V., Shilina N.N. et al. Nonalcoholic fatty liver disease pharmacotherapy: accent on fibrosis. Consilium Medicum. 2018; 20 (8): 37-41. doi: 10.26442/2075-1753_2018.8.37-41 (in Russian).
  27. Стаценко М.Е., Туркина С.В., Шилина Н.Н. Поражение печени у больных с хронической сердечной недостаточностью ишемического генеза и сахарным диабетом типа 2 - коварный тандем: возможности дополнительной органопротективной терапии. Consilium Medi-cum. 2016; 18 (5): 103-9.
  28. Стаценко М.Е., Туркина С.В., Горбачева E.E., Ермоленко А.А. Патогенетические возможности таурина в лечении диабетических микро- и макрососудистых осложнений. Рус. мед. журн. Мед. обозрение 2018; 2 (5): 10-6. @@Statsenko M.E., Turkina S.V., Gorbacheva E.E., Ermolenko A.A. Patogeneticheskie vozmozhnosti taurina v lechenii diabeticheskikh mikro- i makrososudistykh oslozhnenii. Rus. med. zhurn. Med. obozrenie 2018; 2 (5): 10-6 (in Russian).
  29. Стаценко М.Е., Туркина С.В., Шилина Н.Н., Винникова А.А. Эндотелиотропные свойства таурина у больных хронической сердечной недостаточностью и сахарным диабетом 2 типа. Кардиоваск. терапия и профилактика. 2016; 15 (2): 38-44. @@Statsenko M.E., Turkina S.V., Shilina N.N., Vinnikova A.A. Endoteliotropnye svoistva taurina u bol'nykh khronicheskoi serdechnoi nedostatochnost'iu i sakharnym diabetom 2 tipa. Kardiovask. terapiia i profilaktika. 2016; 15 (2): 38-44 (in Russian).
  30. Yilmaz Ergun. The diagnostic role of ultrasonograhyy in liver streatosis. Turk J Gastroenterol 1999; 2: 96-100.
  31. Amato MC, Giordano C, Galia M et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33: 920-2.
  32. Angulo P, Hui JM, Marchesini G et al. The NAFLD Fibrosis Score: A Noninvasive System That Identifies Liver Fibrosis in Patients with NAFLD. Hеpatology 2007; 45 (4): 846-54.
  33. Bedogni G, Bellentani S, Miglioli L et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology 2006; 6: 33-8.
  34. Amato MC et al. Cut-off points of the visceral adiposity index (VAI) identifying a visceral adipose dysfunction associated with cardiometabolic risk in a Caucasian Sicilian population. Lipids Health Dis 2011; 10 (183): 1-8.
  35. Mohammadreza B et al. Prognostic significance of the complex “Visceral Adiposity Index” vs. simple anthropometric measures: Tehran lipid and glucose study. Cardiovasc Diabetol 2012; 11: 20.
  36. Cardona-Alvarado MI, Lopez-Moreno G, Aguilar-Zavala H et al. Relationship of Visceral Adiposity Index with the Metabolic Phenotype and Cardiovascular Markers in Non-Diabetic Subjects. Health Sci J 2018; 12 (5): 588.
  37. Yang F, Wang G, Wang Z et al. Visceral Adiposity Index May Be a Surrogate Marker for the Assessment of the Effects of Obesity on Arterial Stiffness. PLoS ONE 2014; 9 (8): e104365.
  38. Zhang Z, Shi D, Zhang Q et al. Visceral adiposity index (VAI), a powerful predictor of incident hypertension in prehypertensives. Intern Emerg Med 2018; 13: 509-15.
  39. Chaonan Xu, Zhimin Ma, Yunfeng Wang et al. Visceral adiposity index as a predictor of NAFLD: A prospective study with 4-year follow-up. Liver International 2018; 38 (12): 2294-300.
  40. Petta S, Amato MC, Di Marco V et al. Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35: 238-47.
  41. Schuller-Levis GB., Park E. Taurine and its chloramine: modulators of immunity. Neurochem Res 2004;29:117-26.
  42. Kanayama A, Inoue J, Sugita-Konishi Y et al. Oxidation of IkB at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kB activation. J Biol Chem 2002; 277: 24049-56.
  43. Kim KS, Ji HI, Chung H et al. Taurine chloramine modulates the expression of adipokines through inhibition of the STAT-3 signaling pathway in differentiated human adipocytes. Amino Acids 2013; 45:1415-22.
  44. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y et al. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci 2006; 110: 267-78.
  45. Stefan N, Stumvoll M. Adiponectin - its role in metabolism and beyond. Horm Metab Res 2002; 34: 469-74.
  46. You JS, Zhao X, Kim SH et al. Positive correlation between serum taurine and adiponectin levels in high-fat diet-induced obesity rats. Adv. Exp Med Biol 2013; 776: 105-11.
  47. Chen SW, Chen YX, Sh J et al. The restorative effect of taurine on experimental nonalcoholic stea-tohepatitis. Dig Dis Sci 2006; 51: 2225-34.
  48. Rosa FT, Freitas EC, Deminice R et al. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study. Eur J Nutr 2014; 53: 823-30.
  49. Schaffer SW, Jong CJ, Ito T, Azuma J. Role of taurine in the pathologies of MELAS and MERRF. Amino Acids 2014; 46: 47-56.
  50. Das J, Ghosh J, Manna P, Sil PC. Protective role of taurine against arsenic-induced mitochondria-dependent hepatic apoptosis via the inhibition of PKC-JNK pathway. PLoS One 2010; 5: e12602.
  51. Chang L, Xu JX, Zha J et al. Taurine antagonized oxidative stress injury induced by homocysteine in rat vascular smooth muscle cells. Acta Pharmacol Sin 2004; 25: 341-6.
  52. El Idrissi A. Taurine increases mitochondrial buffering of calcium: role in neuroprotection. Amino Acids 2008; 34: 321-8.
  53. Yamamoto K, Yoshitama A, Sakono M et al. Dietary taurine decreases hepatic secretion of cholesterol ester in rats fed a high-cholesterol diet. Pharmacology 2000; 60: 27-33.
  54. Yanagita T, Han SY, Hu Y et al. Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 2008; 7: 38-42.
  55. Chen SW, Chen YX, Shi J et al. The restorative effect of taurine on experimental nonalcoholic steatohepatitis. Dig Dis Sci 2006; 5: 2225-34.
  56. Chang YY, Chou CH, Chiu CH et al. Preventive effects of taurine on development of hepatic steatosis induced by a high-fat/cholesterol dietary habit. J Agric Food Chem 2011; 59: 450-7.
  57. Gentile CL, Nivala AM, Gonzales JC, Pfaffenbach KT. Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver di sease. Am J Physiol Regul Integr Comp Physiol 2011; 301: 1710-22.
  58. Pina-Zentella G, dela Rosa-Cuevas G, Va zquez-Meza et al. Taurine in adipocytes prevents insulin-mediated H2Oj generation and activates Pka and lipolysis. Amino Acids 2012; 42: 1927-35.
  59. Kumari N, Prentice H, Wu JY. Taurine and its neuroprotective role. Adv Exp Med Biol 2013; 775: 19-27.
  60. Albrecht J, Schousboe A. Taurine interaction with neurotransmitter receptors in the CNS: an update. Neurochem Res 2005; 30: 1615-21.
  61. Murakami T, Furuse M. The impact of taurine and beta-alanine-supplemented diets on behavioral and neurochemical parameters in mice: antidepressant versus anxiolytic-like effects. Amino Acids 2010;39: 427-34.
  62. Agouza IME, Saad AH, Mahfouz AA, Hamdy K. Serum Taurine Level in Relation to Ophthalmoscopic Examination as Early Marker for Diabetic Retinopathy. Clin Med Biochemistry 2017; 3: 124-9.
  63. Flavia Troncon R, Freitas EC, Deminice R et al. Oxidative stress and inflammation in obesity after taurine supplementation: a double-blind, placebo-controlled study Eur J Nutr 2014; 53: 823-30.
  64. Agouza IE, Fouad R, Ahmed R et al. Comparison between Fibroscan and Serum Taurine for Early Diagnosis of Liver Fibrosis in Egyptian Patients Infected with HCV. Clin Med Biochem 2017; 3: 127-36.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies